Cargando…
A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel
OBJECTIVES: The effectiveness of remdesivir, a Food and Drug Administration-approved drug for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been repeatedly questioned during the current coronavirus disease 2019 (COVID-19) pandemic. Most of the recently reported studies were rando...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939997/ https://www.ncbi.nlm.nih.gov/pubmed/33705849 http://dx.doi.org/10.1016/j.cmi.2021.02.029 |
_version_ | 1783661857777647616 |
---|---|
author | Goldberg, Elad Ben Zvi, Haim Sheena, Liron Sofer, Summer Krause, Ilan Sklan, Ella H. Shlomai, Amir |
author_facet | Goldberg, Elad Ben Zvi, Haim Sheena, Liron Sofer, Summer Krause, Ilan Sklan, Ella H. Shlomai, Amir |
author_sort | Goldberg, Elad |
collection | PubMed |
description | OBJECTIVES: The effectiveness of remdesivir, a Food and Drug Administration-approved drug for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been repeatedly questioned during the current coronavirus disease 2019 (COVID-19) pandemic. Most of the recently reported studies were randomized controlled multicentre clinical trials. Our goal was to test the efficiency of remdesivir in reducing nasopharyngeal viral load and hospitalization length in a real-life setting in patients admitted to a large tertiary centre in Israel. METHODS: A total of 142 COVID-19 patients found to have at least three reported SARS-CoV-2 quantitative RT-PCR tests during hospitalization were selected for this study. Of these, 29 patients received remdesivir, while the remaining non-treated 113 patients served as controls. RESULTS: Among the tested parameters, the control and remdesivir groups differed significantly only in the intubation rates. Remdesivir treatment did not significantly affect nasopharyngeal viral load, as determined by comparing the differences between the first and last cycle threshold values of the SARS-CoV-2 quantitative RT-PCR tests performed during hospitalization (cycle threshold 7.07 ± 6.85 vs. 7.08 ± 7.27, p 0.977 in the control and treated groups, respectively). Remdesivir treatment shortened hospitalization length by less than a day compared with non-treated controls and by 3.1 days when non-intubated patients from both groups were compared. These differences, however, were not statistically significant, possibly because of the small size of the remdesivir group. DISCUSSION: Remdesivir was not associated with nasopharyngeal viral load changes, but our study had a significant disease severity baseline imbalance and was not powered to detect viral load or clinical differences. |
format | Online Article Text |
id | pubmed-7939997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79399972021-03-09 A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel Goldberg, Elad Ben Zvi, Haim Sheena, Liron Sofer, Summer Krause, Ilan Sklan, Ella H. Shlomai, Amir Clin Microbiol Infect Research Note OBJECTIVES: The effectiveness of remdesivir, a Food and Drug Administration-approved drug for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been repeatedly questioned during the current coronavirus disease 2019 (COVID-19) pandemic. Most of the recently reported studies were randomized controlled multicentre clinical trials. Our goal was to test the efficiency of remdesivir in reducing nasopharyngeal viral load and hospitalization length in a real-life setting in patients admitted to a large tertiary centre in Israel. METHODS: A total of 142 COVID-19 patients found to have at least three reported SARS-CoV-2 quantitative RT-PCR tests during hospitalization were selected for this study. Of these, 29 patients received remdesivir, while the remaining non-treated 113 patients served as controls. RESULTS: Among the tested parameters, the control and remdesivir groups differed significantly only in the intubation rates. Remdesivir treatment did not significantly affect nasopharyngeal viral load, as determined by comparing the differences between the first and last cycle threshold values of the SARS-CoV-2 quantitative RT-PCR tests performed during hospitalization (cycle threshold 7.07 ± 6.85 vs. 7.08 ± 7.27, p 0.977 in the control and treated groups, respectively). Remdesivir treatment shortened hospitalization length by less than a day compared with non-treated controls and by 3.1 days when non-intubated patients from both groups were compared. These differences, however, were not statistically significant, possibly because of the small size of the remdesivir group. DISCUSSION: Remdesivir was not associated with nasopharyngeal viral load changes, but our study had a significant disease severity baseline imbalance and was not powered to detect viral load or clinical differences. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021-06 2021-03-09 /pmc/articles/PMC7939997/ /pubmed/33705849 http://dx.doi.org/10.1016/j.cmi.2021.02.029 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Research Note Goldberg, Elad Ben Zvi, Haim Sheena, Liron Sofer, Summer Krause, Ilan Sklan, Ella H. Shlomai, Amir A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel |
title | A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel |
title_full | A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel |
title_fullStr | A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel |
title_full_unstemmed | A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel |
title_short | A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel |
title_sort | real-life setting evaluation of the effect of remdesivir on viral load in covid-19 patients admitted to a large tertiary centre in israel |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939997/ https://www.ncbi.nlm.nih.gov/pubmed/33705849 http://dx.doi.org/10.1016/j.cmi.2021.02.029 |
work_keys_str_mv | AT goldbergelad areallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT benzvihaim areallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT sheenaliron areallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT sofersummer areallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT krauseilan areallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT sklanellah areallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT shlomaiamir areallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT goldbergelad reallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT benzvihaim reallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT sheenaliron reallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT sofersummer reallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT krauseilan reallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT sklanellah reallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael AT shlomaiamir reallifesettingevaluationoftheeffectofremdesivironviralloadincovid19patientsadmittedtoalargetertiarycentreinisrael |